Download Differentially Expressed Gene Therapy for the Early Detection of

USF Available Technologies
Differentially Expressed Gene
Therapy for the Early Detection of LGL Leukemia
R
esearchers at the University of South Florida have
ADVANTAGES:
discovered a series of both known and novel gene
sequences, which happen to be differentially ex-

leukemia
pressed in LGL leukemia. This technology addresses the
use of these gene sequences as molecular markers and

their possible utility as novel therapeutic targets for the
disease.
T-cell large granular lymphocyte (T-LGL) leukemia is a
chronic human lymphoproliferative disorder associated
with autoimmune disease. It is one of several types of
chronic lymphocytic leukemia, and presents with enlarged
Early Detection and treatment applications for LGL
Advanced detection of the clinical triad of rheumatoid
arthritis, neutropenia, and splenomegaly

Enhanced gene therapy and therapeutic process for early
detection of LGL leukemia and autoimmune disorders

Advanced biological molecular marker applications using a
combination of micro-array, RNase protection assays, and
Northern Blot analysis
lymphocytes with abundant pale cytoplasm containing conspicuous azurophilic granules (Figure 1). Autoimmune features are characteristic of this disease, and many of these
patients present with the triad of rheumatoid arthritis, neutropenia, and an enlarged spleen.
Early Detection and Treatment of LGL
Leukemia
The main indication for treatment of patients with T-LGL is
recurrent infection due to severe neutropenia. Aggressive
cases of T-LGL leukemia are usually treated with combination chemotherapy. Current research suggests that LGL leukemia is likely an antigen driven event. However, independent of the factors involved in the initiation of this disease,
the final effect is the emergence of a lymphoproliferative
disorder with characteristic allocations in a gene expression
pattern. Using a combination of techniques, several genes
have been identified which are differentially expressed in
LGL leukemia and represent promising candidates for early
diagnosis and treatment of LGL leukemia.
Tech ID # 02A027
University of South Florida | Technology Transfer Office
813.974.0994 (office) | 813.974.8490 (fax)
[email protected]
http://www.usf.edu/research-innovation/pl/